-
1
-
-
54949110541
-
Targeting EGFR in colorectal cancer
-
Messersmith WA, Ahnen DJ (2008) Targeting EGFR in colorectal cancer. N Engl J Med 359(17):1834-1836.
-
(2008)
N Engl J Med
, vol.359
, Issue.17
, pp. 1834-1836
-
-
Messersmith, W.A.1
Ahnen, D.J.2
-
2
-
-
79956298812
-
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status
-
Van Cutsem E, et al. (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15):2011-2019.
-
(2011)
J Clin Oncol
, vol.29
, Issue.15
, pp. 2011-2019
-
-
Van Cutsem, E.1
-
3
-
-
79957523828
-
KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
-
De Roock W, et al. (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12(6):594-603.
-
(2011)
Lancet Oncol
, vol.12
, Issue.6
, pp. 594-603
-
-
De Roock, W.1
-
4
-
-
67649506174
-
Genetic prognostic and predictive markers in colorectal cancer
-
Walther A, et al. (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9(7):489-499.
-
(2009)
Nat Rev Cancer
, vol.9
, Issue.7
, pp. 489-499
-
-
Walther, A.1
-
5
-
-
33646352962
-
Potent antibody therapeutics by design
-
Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6(5): 343-357.
-
(2006)
Nat Rev Immunol
, vol.6
, Issue.5
, pp. 343-357
-
-
Carter, P.J.1
-
6
-
-
61449239114
-
Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan
-
Bibeau F, et al. (2009) Impact of FcgammaRIIa-FcgammaRIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 27(7):1122-1129.
-
(2009)
J Clin Oncol
, vol.27
, Issue.7
, pp. 1122-1129
-
-
Bibeau, F.1
-
7
-
-
62449302407
-
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
-
Sartore-Bianchi A, et al. (2009) PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res 69(5):1851-1857.
-
(2009)
Cancer Res
, vol.69
, Issue.5
, pp. 1851-1857
-
-
Sartore-Bianchi, A.1
-
8
-
-
74249093155
-
PTEN status in advanced colorectal cancer treated with cetuximab
-
Negri FV, et al. (2010) PTEN status in advanced colorectal cancer treated with cetuximab. Br J Cancer 102(1):162-164.
-
(2010)
Br J Cancer
, vol.102
, Issue.1
, pp. 162-164
-
-
Negri, F.V.1
-
9
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
-
De Roock W, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy- refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11(8):753-762.
-
(2010)
Lancet Oncol
, vol.11
, Issue.8
, pp. 753-762
-
-
De Roock, W.1
-
10
-
-
80054718129
-
A phase II trial of lapatinib and capecitabine for patients with refractory advanced colorectal adenocarcinoma
-
abstr
-
Frank D, et al. (2010) A phase II trial of lapatinib and capecitabine for patients with refractory advanced colorectal adenocarcinoma. J Clin Oncol 28(suppl; abstr):e14092.
-
(2010)
J Clin Oncol
, vol.28
, Issue.SUPPL.
-
-
Frank, D.1
-
11
-
-
53249123419
-
Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: A fluorescent in situ hybridization study
-
Personeni N, et al. (2008) Clinical usefulness of EGFR gene copy number as a predictive marker in colorectal cancer patients treated with cetuximab: A fluorescent in situ hybridization study. Clin Cancer Res 14(18):5869-5876.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.18
, pp. 5869-5876
-
-
Personeni, N.1
-
12
-
-
77950673501
-
Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer
-
Hecht JR, et al. (2010) Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res 16(7):2205-2213.
-
(2010)
Clin Cancer Res
, vol.16
, Issue.7
, pp. 2205-2213
-
-
Hecht, J.R.1
-
13
-
-
73349098041
-
Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab
-
Jacobs B, et al. (2009) Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 27(30):5068-5074.
-
(2009)
J Clin Oncol
, vol.27
, Issue.30
, pp. 5068-5074
-
-
Jacobs, B.1
-
14
-
-
70449427821
-
Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis
-
Ashraf SQ, et al. (2009) Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br J Cancer 101(10):1758-1768.
-
(2009)
Br J Cancer
, vol.101
, Issue.10
, pp. 1758-1768
-
-
Ashraf, S.Q.1
-
15
-
-
33645218704
-
Engineered antibody Fc variants with enhanced effector function
-
Lazar GA, et al. (2006) Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 103(11):4005-4010.
-
(2006)
Proc Natl Acad Sci USA
, vol.103
, Issue.11
, pp. 4005-4010
-
-
Lazar, G.A.1
-
16
-
-
77955058495
-
5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency
-
Bracht K, et al. (2010) 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency. Br J Cancer 103(3):340-346.
-
(2010)
Br J Cancer
, vol.103
, Issue.3
, pp. 340-346
-
-
Bracht, K.1
-
17
-
-
77949957365
-
Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents
-
Sharma SV, et al. (2010) Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat Rev Cancer 10(4):241-253.
-
(2010)
Nat Rev Cancer
, vol.10
, Issue.4
, pp. 241-253
-
-
Sharma, S.V.1
-
18
-
-
84859187259
-
Systematic identi fication of genomic markers of drug sensitivity in cancer cells
-
Garnett MJ, et al. (2012) Systematic identi fication of genomic markers of drug sensitivity in cancer cells. Nature 483(7391):570-575.
-
(2012)
Nature
, vol.483
, Issue.7391
, pp. 570-575
-
-
Garnett, M.J.1
-
19
-
-
84859169877
-
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
-
Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607.
-
(2012)
Nature
, vol.483
, Issue.7391
, pp. 603-607
-
-
Barretina, J.1
-
20
-
-
40949135397
-
PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab
-
Jhawer M, et al. (2008) PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. Cancer Res 68(6):1953-1961.
-
(2008)
Cancer Res
, vol.68
, Issue.6
, pp. 1953-1961
-
-
Jhawer, M.1
-
21
-
-
33747886889
-
Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib
-
Cunningham MP, et al. (2006) Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib. Cancer Res 66(15):7708-7715.
-
(2006)
Cancer Res
, vol.66
, Issue.15
, pp. 7708-7715
-
-
Cunningham, M.P.1
-
22
-
-
65649086786
-
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer
-
Prenen H, et al. (2009) PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer. Clin Cancer Res 15(9):3184-3188.
-
(2009)
Clin Cancer Res
, vol.15
, Issue.9
, pp. 3184-3188
-
-
Prenen, H.1
-
23
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
Di Nicolantonio F, et al. (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26(35):5705-5712.
-
(2008)
J Clin Oncol
, vol.26
, Issue.35
, pp. 5705-5712
-
-
Di Nicolantonio, F.1
-
24
-
-
84863230465
-
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
-
Prahallad A, et al. (2012) Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483(7387):100-103.
-
(2012)
Nature
, vol.483
, Issue.7387
, pp. 100-103
-
-
Prahallad, A.1
-
25
-
-
79551580548
-
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
-
Baker JB, et al. (2011) Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer 104(3):488-495.
-
(2011)
Br J Cancer
, vol.104
, Issue.3
, pp. 488-495
-
-
Baker, J.B.1
-
26
-
-
53249137803
-
Molecular association between beta-catenin degradation complex and Rac guanine exchange factor DOCK4 is essential for Wnt/beta-catenin signaling
-
Upadhyay G, et al. (2008) Molecular association between beta-catenin degradation complex and Rac guanine exchange factor DOCK4 is essential for Wnt/beta-catenin signaling. Oncogene 27(44):5845-5855.
-
(2008)
Oncogene
, vol.27
, Issue.44
, pp. 5845-5855
-
-
Upadhyay, G.1
-
27
-
-
17844362179
-
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: A cohort study
-
Moroni M, et al. (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6(5):279-286.
-
(2005)
Lancet Oncol
, vol.6
, Issue.5
, pp. 279-286
-
-
Moroni, M.1
-
28
-
-
20144381957
-
Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry
-
Chung KY, et al. (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23(9):1803-1810.
-
(2005)
J Clin Oncol
, vol.23
, Issue.9
, pp. 1803-1810
-
-
Chung, K.Y.1
-
29
-
-
46249087766
-
Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members
-
Wheeler DL, et al. (2008) Mechanisms of acquired resistance to cetuximab: Role of HER (ErbB) family members. Oncogene 27(28):3944-3956.
-
(2008)
Oncogene
, vol.27
, Issue.28
, pp. 3944-3956
-
-
Wheeler, D.L.1
-
30
-
-
0022446735
-
Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms
-
Epenetos AA, Snook D, Durbin H, Johnson PM, Taylor-Papadimitriou J (1986) Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46(6):3183-3191.
-
(1986)
Cancer Res
, vol.46
, Issue.6
, pp. 3183-3191
-
-
Epenetos, A.A.1
Snook, D.2
Durbin, H.3
Johnson, P.M.4
Taylor-Papadimitriou, J.5
-
31
-
-
0035256698
-
Untangling the ErbB signalling network
-
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127-137.
-
(2001)
Nat Rev Mol Cell Biol
, vol.2
, Issue.2
, pp. 127-137
-
-
Yarden, Y.1
Sliwkowski, M.X.2
-
32
-
-
0033044588
-
Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity
-
Umaña P, et al. (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17(2):176-180.
-
(1999)
Nat Biotechnol
, vol.17
, Issue.2
, pp. 176-180
-
-
Umaña, P.1
-
33
-
-
80053644648
-
Phase i pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors
-
Paz-Ares LG, et al. (2011) Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 29(28):3783-3790.
-
(2011)
J Clin Oncol
, vol.29
, Issue.28
, pp. 3783-3790
-
-
Paz-Ares, L.G.1
|